Infringement of U.S. Patent No. 5,597,815 ("Prevention of Hyperphosphatemia in Kidney Disorder Patients," issued January 28, 1997) based on Banner's filing of an NDA (under § 505(b)(2) of the Food, Drug and Cosmetic Act) to manufacture a generic version of Abbott's Zemplar® (paricalcitol, used to treat secondary hyperparathyroidism in patients with kidney failure). View the complaint here.

Ivax LLC v. Celgene Corp.
0:12-cv-61917; filed September 28, 2012 in the Southern District of Florida

Infringement of U.S. Patent No. 7,759,481 ("Solid State Forms of 5-Azacytidine and Processes for Preparation Thereof," issued July 20, 2010) based on Celgene's manufacture and sale of its Vidaza® (azacitidine, used to treat myelodysplastic syndrome). View the complaint here.

Gilead Sciences, Inc. v. Kappos
1:12-cv-01090; filed September 27, 2012 in the Eastern District of Virginia

Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 8,148,374 ("Modulators of Pharmacokinetic Properties of Therapeutics," issued April 3, 2012). View the complaint here.

Genetic Technologies Ltd. v. Medical Diagnostic Laboratories, L.L.C.
3:12-cv-06053; filed September 26, 2012 in the District Court of New Jersey

Genetic Technologies Ltd. v. Reprogenetics, L.L.C.
2:12-cv-06052; filed September 26, 2012 in the District Court of New Jersey

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.